GUDKnight Therapeutics Inc.TSXHealth Care
C$11.61−C$0.09Down0.77%Oct 26, 2026 close
Coming Soon
Format:
METRIC
TTM
Dec 25
Dec 24
Dec 23
Period Ending—Dec 31, 2025Dec 31, 2024Dec 31, 2023
Revenue
Revenue$533M$450M$371M$328M
Cost of Revenue$285M$250M$197M$176M
Gross Profit$248M$200M$174M$153M
Operating
Operating Income$22.1M-$2.35M$7.40M$6.37M
EBITDA$80.5M$54.2M$60.5M$56.8M
Pre-Tax Income$7.69M-$6.70M$2.05M-$22.0M
Income Tax Expense$1.65M-$1.33M-$2.28M-$5.15M
Net Income$6.04M-$5.37M$4.33M-$16.8M
Per Share
EPS (Basic)$0.06$-0.05$0.04$-0.16
EPS (Diluted)$0.06$-0.05$0.04$-0.16
Shares Basic99.0M99.6M101M107M
Shares Diluted99.2M99.6M101M107M
Dividend Per Share————
Margins
Gross Margin+46.6%+44.5%+47.0%+46.5%
EBIT Margin+4.1%-0.5%+2.0%+1.9%
EBITDA Margin+15.1%+12.0%+16.3%+17.3%
Net Margin+1.1%-1.2%+1.2%-5.1%
Effective Tax Rate+21.5%+19.8%-111.1%+23.4%
Growth
Revenue Growth—+21.2%+13.1%+11.8%
Net Income Growth—-224.1%+125.7%+43.7%
EPS Growth—-225.0%+125.0%+38.5%
Share Count Change—-1.8%-5.6%-6.5%
Free Cash Flow
Free Cash Flow$89.1M$35.3M$4.81M$26.0M
FCF Per Share$0.90$0.35$0.05$0.24
FCF Margin+16.7%+7.8%+1.3%+7.9%
FCF Growth—+633.4%-81.5%+35.4%
© 2026 WallStMonk. All rights reserved. v0.19.39Not investment advice · Data as of previous market close